Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11869494 | 0.88 | ALDH1A1 (0.52) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL29918523 | 0.88 | ALDH1A1 (0.52) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL96219 | 0.84 | ALDH1A1 (0.48) | ERN1ESR1ESR2ALDH1A1TSHR | |
| SCHEMBL29708014 | 0.84 | ALDH1A1 (0.48) | ERN1ESR1ESR2ALDH1A1TSHR | |
| SCHEMBL3360913 | 0.82 | CYP2A6 (0.46) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL30302136 | 0.82 | ALDH1A1 (0.54) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL5265352 | 0.82 | ALDH1A1 (0.54) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL31227833 | 0.81 | TNKS2 (0.47) | ERN1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4895767 | 0.78 | MAPT (0.44) | ESR1MEN1KMT2AESR2ALDH1A1 | |
| SCHEMBL4895760 | 0.78 | MAPT (0.44) | ESR1MEN1KMT2AESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | claimed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1620392-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-27 | — | — | US | disclosed |
| WO-2004099122-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | ERN1 2045/4885ESR1 1/4885MEN1 3310/4885 |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRB | ERN1 2045/4885ESR1 1/4885MEN1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.